Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 247

The DOI matches its Crossref record.

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

Open access
Viale, Giuseppe, On the behalf of the International Breast Cancer Study Group, Regan, Meredith M., On the behalf of the International Breast Cancer Study Group, Mastropasqua, Mauro G., On the behalf of the International Breast Cancer Study Group, Maffini, Fausto, On the behalf of the International Breast Cancer Study Group, Maiorano, Eugenio, On the behalf of the International Breast Cancer Study Group, Colleoni, Marco, On the behalf of the International Breast Cancer Study Group, Price, Karen N., On the behalf of the International Breast Cancer Study Group, Golouh, Rastko, On the behalf of the International Breast Cancer Study Group, Perin, Tiziana, On the behalf of the International Breast Cancer Study Group, Brown, R. W., On the behalf of the International Breast Cancer Study Group, Kovács, Anikó, On the behalf of the International Breast Cancer Study Group, Pillay, Komala, On the behalf of the International Breast Cancer Study Group, Öhlschlegel, Christian, On the behalf of the International Breast Cancer Study Group, Gusterson, Barry A., On the behalf of the International Breast Cancer Study Group, Castiglione-Gertsch, Monica, On the behalf of the International Breast Cancer Study Group, Gelber, Richard D., On the behalf of the International Breast Cancer Study Group, Goldhirsch, Aron, On the behalf of the International Breast Cancer Study Group, Coates, Alan S., On the behalf of the International Breast Cancer Study Group · 2008 · JNCI: Journal of the National Cancer Institute

Abstract

Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djm289

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 247

Metadata

Authors
Viale, G., On the behalf of the International Breast Cancer Study Group, Regan, M. M., On the behalf of the International Breast Cancer Study Group, Mastropasqua, M. G., On the behalf of the International Breast Cancer Study Group, Maffini, F., On the behalf of the International Breast Cancer Study Group, Maiorano, E., On the behalf of the International Breast Cancer Study Group, Colleoni, M., On the behalf of the International Breast Cancer Study Group, Price, K. N., On the behalf of the International Breast Cancer Study Group, Golouh, R., On the behalf of the International Breast Cancer Study Group, Perin, T., On the behalf of the International Breast Cancer Study Group, Brown, R. W., On the behalf of the International Breast Cancer Study Group, Kovács, A., On the behalf of the International Breast Cancer Study Group, Pillay, K., On the behalf of the International Breast Cancer Study Group, Öhlschlegel, C., On the behalf of the International Breast Cancer Study Group, Gusterson, B. A., On the behalf of the International Breast Cancer Study Group, Castiglione-Gertsch, M., On the behalf of the International Breast Cancer Study Group, Gelber, R. D., On the behalf of the International Breast Cancer Study Group, Goldhirsch, A., On the behalf of the International Breast Cancer Study Group, Coates, A. S., & On the behalf of the International Breast Cancer Study Group
Venue
JNCI: Journal of the National Cancer Institute
Published
2008-02
Volume
100
Issue
3
Pages
207-212
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2112894406
Cited by
247
References
0
FWCI
6.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. https://app.cochat.ai/papers/10.1093/jnci/djm289
The paper
Viale, G., On the behalf of the International Breast Cancer Study Group, Regan, M. M., On the behalf of the International Breast Cancer Study Group, Mastropasqua, M. G., On the behalf of the International Breast Cancer Study Group, Maffini, F., On the behalf of the International Breast Cancer Study Group, Maiorano, E., On the behalf of the International Breast Cancer Study Group, Colleoni, M., On the behalf of the International Breast Cancer Study Group, Price, K. N., On the behalf of the International Breast Cancer Study Group, Golouh, R., On the behalf of the International Breast Cancer Study Group, Perin, T., On the behalf of the International Breast Cancer Study Group, Brown, R. W., . . . On the behalf of the International Breast Cancer Study Group. (2008). Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djm289

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.